Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 48, Issue 3, pp 382–386 | Cite as

Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis

  • Nathan T. ConnellEmail author
  • Jean M. Connors
Article

Abstract

Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome. The direct oral anticoagulant edoxaban has been shown to be noninferior to dalteparin for the treatment of cancer-associated thrombosis. In a Markov simulation model, edoxaban with 6-month time horizon and a United States societal perspective with 2017 US dollars, edoxaban was the preferred strategy in the general cancer population (6-month cost $6061 with 0.34 quality adjusted life years) and in a subgroup of patients with gastrointestinal malignancy (6-month cost $7227 with 0.34 quality adjusted life years). The incremental cost effectiveness ratio of dalteparin compared to edoxaban was $1,873,535 in the general oncology population and $694,058 in the gastrointestinal malignancy population.

Keywords

Cost-effectiveness Edoxaban Dalteparin Cancer-associated thrombosis Venous thromboembolism 

Notes

Author contributions

NTC and JMC designed the study, analyzed the data, critically evaluated and edited the manuscript, and provided final approval. NTC built the Markov model and ran the analyses.

Compliance with ethical standards

Conflict of interest

NT.C.: no financial conflicts of interest. J.M.C.: Honoraria or consulting fees from Bristol-Myers Squibb, Portola, Research funding to the institution CSL Behring.

References

  1. 1.
    Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C (2017) Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 117(1):57–65CrossRefGoogle Scholar
  2. 2.
    Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153CrossRefGoogle Scholar
  3. 3.
    Connell NT, Abel GA, Connors JM (2017) Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis. Thromb Res 150:53–58CrossRefGoogle Scholar
  4. 4.
    Shah S, Rubin N, Khorana AK. Economic burden of venous thromboembolism in cancer patients—a comparative analysis between matched patients with cancer with and without a diagnosis of venous thromboembolism. Blood. 2018;132(366):Abstract 366Google Scholar
  5. 5.
    Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624CrossRefGoogle Scholar
  6. 6.
    Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023CrossRefGoogle Scholar
  7. 7.
    Aujesky D, Smith KJ, Cornuz J, Roberts MS (2005) Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb Haemost 93(3):592–599CrossRefGoogle Scholar
  8. 8.
    Dalteparin. In: RED BOOK Online [database on the Internet]. Greenwood Village (CO): Truven health analytics; January 15, 2018. www.micromedexsolutions.com
  9. 9.
    Edoxaban. In: RED BOOK Online [database on the Internet]. Greenwood Village (CO): Truven health analytics; January 15, 2018. www.micromedexsolutions.com
  10. 10.
    Shah A, Shewale A, Hayes CJ, Martin BC (2016) Cost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patients. Stroke 47(6):1555–1561CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Hematology DivisionBrigham and Women’s HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA

Personalised recommendations